Compare · DXCM vs UTMD
DXCM vs UTMD
Side-by-side comparison of DexCom Inc. (DXCM) and Utah Medical Products Inc. (UTMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and UTMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.76B, about 111.1x UTMD ($213.9M).
- Over the past year, DXCM is down 13.5% and UTMD is up 30.9% - UTMD leads by 44.4 points.
- DXCM has been more active in the news (4 items in the past 4 weeks vs 2 for UTMD).
- DXCM has more recent analyst coverage (25 ratings vs 0 for UTMD).
- Company
- DexCom Inc.
- Utah Medical Products Inc.
- Price
- $61.55-1.84%
- $67.46+0.13%
- Market cap
- $23.76B
- $213.9M
- 1M return
- -7.89%
- +5.86%
- 1Y return
- -13.51%
- +30.94%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Utah Medical Products Inc.
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)
Latest UTMD
- Utah Medical Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2026
- SEC Form DEF 14A filed by Utah Medical Products Inc.
- SEC Form 10-K filed by Utah Medical Products Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Utah Medical Products Inc.
- Utah Medical Products, Inc. Announces Quarterly Dividend
- Utah Medical Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- UTMD Reports Year 2025 and Fourth Quarter Financial Performance
- SEC Form 3 filed by new insider Timken Kevin
- SEC Form 4 filed by Principal Financial Officer Koopman Brian